Archive

Author: Anand Swaminathan

REBEL Cast Ep97: The NoPAC Trial – TXA for Epistaxis?

Background: Epistaxis is a common Emergency Department (ED) complaint with over 450,000 visits per year and a lifetime incidence of 60% (Gifford 2008, Pallin 2005). Standard anterior epistaxis treatment consists of holding pressure, use of local vasoconstrictors, topical application of ...

Read More
Head, Eye, Ear, Nose, and Throat

REBEL Core Cast 50.0 – Superficial Venous Thrombosis

Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation.  The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.

Read More
Hematology and Oncology

Does D Stand for Decrease Deterioration + Death? – The Jury is Out for Vitamin D in COVID

Update: This article was removed from the Lancet server on February 19th, 2021 (Link) Background: Vitamin D deficiency is common amongst critically ill patients and there has been ample speculation about a possible role for supplementation (with calcifediol) in the ...

Read More
Infectious Disease

REBEL Cast Ep95: Colchicine in COVID (COLCORONA)? Don’t Believe the Hype.

Background: Science by press release. Not the way any of us would choose to operate but, the COVID pandemic has made this a reality. It’s vital that we understand that while pharmaceutical companies have a responsibility to release this information, ...

Read More
Infectious Disease

REBEL Core Cast 49.0 – Abdominal Aortic Aneurysm (AAA)

Take Home Points Consider ruptured AAA in patients (especially those > 50 years of age) with unexplained hypotension, back or abdominal pain All ruptured AAAs should be considered unstable regardless of vital signs as rapid deterioration is common A ruptured ...

Read More
Cardiovascular
Showing Slide 1 of 6

Sponsored